...a couple of weeks ago for GHI...based on DCF...much more relevant than PE for biotechs)
12/13/2010-12:12 PM ET PRICE AT PUBLICATION: $ 22.45 GHDX announced results from 7 new studies on its Oncotype DX breast cancer test. The studies confirmed Oncotype DX's recurrence score to accurately predict chemotherapy benefit and recurrence risk in early-stage breast cancer patients. We believe these confirmatory findings will lead to more physicians to use the Oncotype DX tests vs. traditional parameters to help guide treatment decisions. GHDX also recently announced top-line data from its prostate cancer study and will proceed with full clinical development. We are raising our 12-mo. target price $6 to $28 on revised DCF.